A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

Phase 3

Tucatinib & Trastuzumab, mFOLFOX6A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Sponsor:

Seagen, a wholly owned subsidiary of Pfizer

Code:

NCT05253651

Conditions

Colorectal Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

tucatinib

trastuzumab

bevacizumab

cetuximab

oxaliplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-14. This information was provided to ClinicalTrials.gov by Seagen, a wholly owned subsidiary of Pfizer on 2025-09-12.